While other CRO’s are busy merging, Medpace is busy managing.
M&A activity continues in the CRO industry with the recent announcement of two of the largest CROs merging. But while the rest of the CRO industry has grown primarily through mergers and acquisitions, Medpace has expanded through disciplined organic growth—expanding globally to operations in 39 countries and approximately 3,500 employees. Over decades, we’ve systematically added specialized medical, regulatory and operational experts, and refined and enhanced custom-built technologies and processes to best serve the needs of our clients. The result is a culture built on quality that has not been disrupted by acquisitions, and that delivers ongoing efficiencies and stability.
While other CROs are busy merging, Medpace is heads-down managing some of the industry’s most complex and promising clinical studies. If you are concerned about how a merger might impact the momentum of your clinical development, contact us to discuss your project.
Making the Complex Seamless
We can’t simplify clinical development – but we can execute it seamlessly. Medpace provides a therapeutically focused, integrated, global approach for seamless execution and quality results.
A Full Service Philosophy
We know from our long-standing relationships with Sponsors that the full-service outsourcing model ultimately delivers higher quality results.
Trusted by Biotech
Over 90% of our clients are small to medium-sized biopharma companies. We understand the unique challenges because we’ve been partnering with emerging biotechs since our inception in 1992.